COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00184366
Recruitment Status : Terminated (efalizumab was withdrawn from market; full 2 years follow-up only 14 patients)
First Posted : September 16, 2005
Last Update Posted : January 19, 2012
Information provided by (Responsible Party):
Norwegian University of Science and Technology

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 2008
Actual Study Completion Date : July 2008